A. Chakravartty

发表

Patient subgroup identification for clinical drug development

V. Devanarayan, L. Tian, S. Chatterjee, 2017, Statistics in medicine.

Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies.

E. Felip, D. Planchard, L. Paz-Ares, 2016 .

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

L. Chow, A. Bardia, F. Cardoso, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase 3 randomized MONALEESA-3 trial: updated overall survival.

P. Fasching, P. Neven, S. Im, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

P. Fasching, P. Neven, F. Esteva, 2019, The New England journal of medicine.

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.

L. Chow, A. Bardia, N. Harbeck, 2019, The New England journal of medicine.

LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)

P. Fasching, P. Neven, C. Wang, 2022, Annals of Oncology.

LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)

G. Hortobagyi, M. Campone, L. Hart, 2021, Annals of Oncology.

Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib

L. Chow, A. Bardia, N. Harbeck, 2021 .

Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).

P. Fasching, P. Neven, D. Slamon, 2021, Journal of Clinical Oncology.

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.

Sung-Bae Kim, A. Dechaphunkul, É. Remenár, 2017, The Lancet. Oncology.

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

G. Giaccone, C. Rudin, M. Ranson, 2012, Clinical Cancer Research.

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.

B. Mellado, J. Machiels, L. Dirix, 2017, European journal of cancer.

In Vivo Assay Guidelines

S. Iturria, P. Iversen, Hui-Rong Qian, 2004 .

Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib.

V. Devanarayan, S. Ramalingam, P. Ansell, 2015, Lung cancer.

Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.

L. Chow, A. Bardia, N. Harbeck, 2019, Journal of Clinical Oncology.

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.

E. Winer, G. Hortobagyi, F. André, 2022, The New England journal of medicine.

Pharmacodynamic Evaluation of Irinotecan Therapy by FDG and FLT PET/CT Imaging in a Colorectal Cancer Xenograft Model

M. Day, P. Tapang, G. Fox, 2012, Molecular Imaging and Biology.

Phenotypic Fingerprinting of Small Molecule Cell Cycle Kinase Inhibitors for Drug Discovery

Jonathan Low, Arunava Chakravartty, Jonathan Low, 2009, Current chemical genomics.

A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model

Gerard B. Fox, Vincent P. Hradil, Bryan F. Cox, 2012, Cancer Chemotherapy and Pharmacology.

Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

P. Neven, F. Esteva, X. Pivot, 2019, Annals of Oncology.

Cancer Therapy : Clinical Phase II Study of Single-Agent Navitoclax ( ABT-263 ) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

G. Giaccone, C. Rudin, G. Shapiro, 2012 .

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer

S. Loi, G. Hortobagyi, A. Bardia, 2023, Therapeutic advances in medical oncology.

Multi-omics investigation on the prognostic and predictive factors in metastatic breast cancer using data from Phase III ribociclib clinical trials: A statistical and machine learning analysis plan

Ravi K. Samala, Luis V. Santana-Quintero, Kenny H. Cha, 2023, medRxiv.

BERIL-1: A phase II, placebo-controlled study of buparlisib (BKM120) plus paclitaxel in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

Sung-Bae Kim, A. Dechaphunkul, É. Remenár, 2016 .

Use of Adaptive Design in Late-Stage Oncology Trials

Satrajit Roychoudhury, P. Mukhopadhyay, A. Chakravartty, 2018, Statistical Approaches in Oncology Clinical Development.

Some Observations in Likelihood Based Fitting of Longitudinal Models for Binary Data

Subir Ghosh, Arunava Chakravartty, Subir Ghosh, 2021, Journal of Data Science.

Effectiveness of Bootstrap Bias Correction in the Context of Clock Offset Estimators

Daniel R. Jeske, Arunava Chakravartty, A. Chakravartty, 2006, Technometrics.

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant

P. Neven, C. Wang, G. Jerusalem, 2023, Breast Cancer Research.

Methodology for Good Machine Learning with Multi‐Omics Data

Kenny H. Cha, B. Sahiner, D. Ohlssen, 2023, Clinical pharmacology and therapeutics.

Ribociclib plus Endocrine Therapy in Early Breast Cancer.

G. Hortobagyi, D. Yardley, M. Ruíz-Borrego, 2024, The New England journal of medicine.